4th World Bronchiectasis & NTM Conference

EMBARC
The European Bronchiectasis Registry

Virtual Edition
16-19 December 2020

www.world-bronchiectasis-conference.org
Dear Colleagues and Friends,

It is our great pleasure to welcoming you to the 4th World Bronchiectasis & NTM Conference virtual edition that will be held from 16 to 19 December 2020.

In a year characterized by the COVID – 19 Pandemic with most of the healthcare resources and energies concentrated in fighting the infection, the World Bronchiectasis Conference remains the place where the latest outcomes on the diagnosis and management of Bronchiectasis are shared and discussed for the benefit and care of chronic and fragile patients.

Furthermore, following the increase of NTM pulmonary and extra – pulmonary morbidity and mortality, it has been decided to fully integrate NTM related topics within the conference programme transforming the WBN – Word Bronchiectasis Conference in WBNC – World Bronchiectasis & NTM Conference.

Considering the complex clinical picture of most of the patients affected by Bronchiectasis and NTM, large space will be given in this edition to co-morbidities. A central role would be also dedicated to the latest outcome on microbiome in pulmonary diseases as well as in the latest outcomes in clinical trials, and new available diagnostic procedures and treatments. The conference will also be the place to discuss the International Guidelines on NTM and Bronchiectasis.

Several lectures would be reserved to latest and most interesting researches from all over the World presented directly by participants, while poster sessions will help sharing effective clinical practices among attendees.

Joining forces, exchanging clinical experiences, sharing data and instruments, creating a network of active experts in the field are the main goals of the conference.

We look forward to having you all connected,

Yours Sincerely,

Prof. Antoni TORRES
Prof. Francesco BLASI
GENERAL INFORMATION

Live sessions and contents of the
4th World Bronchiectasis & NTM Conference
available on:
www.world-bronchiectasis-conference.org

ORGANISER

EMBARC
The European Bronchiectasis Registry

SCIENTIFIC & ORGANISING SECRETARIAT

Publi Créations
wbc@publiccreations.com
+377 97973555
Conference Chair

Professor Antoni Torres (Spain)
Full Professor in Medicine (Pulmonology) at the University of Barcelona and Director of the Respiratory Intensive Care Unit at Hospital Clinic.
Chair of the research group on Applied Research in Respiratory Diseases of the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).
Coordinator of the CIBER group on respiratory diseases (Ciberes), an SGR (Generalitat de Catalonia) group.
Member of EMBARC (The European Bronchiectasis Network) Steering Committee.

Conference Co-Chair

Professor Francesco Blasi (Italy)
Professor of Respiratory Medicine and Head of the Department of Pathophysiology and Transplantation at the University of Milan.
Head Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan.
Member of Board of Directors, Università degli Studi di Milano.
Member of EMBARC (The European Bronchiectasis Network) Steering Committee.
Co-chair of IRIDE, the Italian Registry of adult bronchiectasis.
Co-chair of IRENE the Italian Observatory on Non-Tuberculous Mycobacteria
Former President of ERS – European Respiratory Society.
SCIENTIFIC COMMITTEE

Antoni Torres, Barcelona, Spain
Francesco Blasi, Milan, Italy

Timothy Aksamit, Rochester, USA
Stefano Aliberti, Milan, Italy
James D. Chalmers, Dundee, UK
Wei-Jie Guan, Guangzhou, China
Lucy Morgan, Sydney, Australia
Michal Shteinberg, Haifa, Israel
Montserrat Vendrell, Girona, Spain
Tobias Welte, Hannover, Germany

TOPICS

ABPA - Allergic bronchopulmonary aspergillosis
Alpha-1 antitrypsin deficiency
Asthma
Biomarkers
Bronchiectasis
Comorbidities
COPD
Cystic Fibrosis
Exacerbations
Genetics
Immunodeficiency
Inhaled Antibiotics
Inhaled Steroids
International Guidelines
Lung Function Testing
Microbiome & Mycobioime
NTM – Non-Tuberculous Mycobacteria
Physiotherapy
PCD - Primary Ciliary Dyskinesia
Registries
Research priorities
RCT – Randomized Clinical Trials
Severity Scores
FACULTY

Tim Aksamit, Rochester, USA
Stefano Aliberti, Milan, Italy
Alan Barker, Portland, USA
Francesco Blasi, Milan, Italy
James D. Chalmers, Dundee, UK
Anne Chang, Brisbane, Australia
Sanjay Chotirmall, Singapore
Tanya Coulter, Belfast, UK
Ernesto Crisafulli, Verona, Italy
Margot de Koning Gans, Christchurch, New Zealand
David de la Rosa Carrillo, Barcelona, Spain
Antony De Soyza, Newcastle, UK
Raja Dhar, Kolkata, India
Gisli Einarsson, Belfast, United Kingdom
Stuart Elborn, Belfast, UK
Laia Fernandez, Barcelona, Spain
Andreas Floto, Cambridge, UK
Yong-hua Gao, Zhengzou, China
Timm Greulich, Marburg, Germany
David E. Griffith, Denver, USA
Wei-Jie Guan, Guangzhou, China
Charles Haworth, Cambridge, UK
Adam Hill, Edinburgh, UK
Holly Keir, Dundee - United Kingdom
Michael Loebinger, London, UK
Nicola Lorè, Milan, Italy
Miguel Angel Martinez-Garcia, Valencia, Spain
Aurora Massaguer, Girona, Spain
Jennifer Meerburg, Rotterdam, The Netherlands
Rosario Menendez, Valencia, Spain
Mark Metersky, Farmington, USA
Anne O’Donnell, Washington DC, USA
Lucy Morgan, Sydney, Australia
Kenneth Olivier, Bethesda, USA
Constança Pascual, Girona, Spain
Eva Polverino, Barcelona, Spain
Felix Ringshausen, Hannover, Germany
Jodie Schildkraut, Nijmegen, The Netherlands
Leopoldo Segal, New York, USA
Michal Shteinberg, Haifa, Israel
Oriol Sibila, Barcelona, Spain
Gregory Tino, Philadelphia, USA
Antoni Torres, Barcelona, Spain
Jakko van Ingen, Nijmegen, The Netherlands
Montserrat Vendrell, Girona, Spain
Nicola Veziris, Paris, France
Alexandru D. Vlagea, Barcelona, Spain
Tobias Welte, Hannover, Germany
Kevin Winthrop, Portland, USA
### POSTER PRESENTERS

<table>
<thead>
<tr>
<th>Presenters</th>
<th>Poster N.</th>
<th>See Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abo-Leyah Hani</td>
<td>19.b.1</td>
<td>16</td>
</tr>
<tr>
<td>Alcaraz Victoria</td>
<td>19.b.9</td>
<td>16</td>
</tr>
<tr>
<td>Alfahl Zina</td>
<td>19.a.1</td>
<td>15</td>
</tr>
<tr>
<td>Alhamed Alduihi Fatima</td>
<td>19.a.2</td>
<td>15</td>
</tr>
<tr>
<td>Alkarni Meyad</td>
<td>18.c.1</td>
<td>14</td>
</tr>
<tr>
<td>Athanazio Rodrigo Abensur</td>
<td>18.a.1</td>
<td>12</td>
</tr>
<tr>
<td>Athanazio Rodrigo Abensur</td>
<td>18.a.2</td>
<td>12</td>
</tr>
<tr>
<td>Bhatnagar Malvika</td>
<td>19.a.3</td>
<td>15</td>
</tr>
<tr>
<td>Blamires Julie</td>
<td>19.a.4</td>
<td>15</td>
</tr>
<tr>
<td>Bradley Judy M.</td>
<td>19.a.5</td>
<td>15</td>
</tr>
<tr>
<td>Bradley Judy M.</td>
<td>19.a.6</td>
<td>15</td>
</tr>
<tr>
<td>Bueno Freire Leticia</td>
<td>19.a.7</td>
<td>15</td>
</tr>
<tr>
<td>Cabrera Roberto</td>
<td>18.a.3</td>
<td>12</td>
</tr>
<tr>
<td>Crichton Megan L.</td>
<td>18.a.4</td>
<td>12</td>
</tr>
<tr>
<td>De Vuono Maria Carmela</td>
<td>18.a.5</td>
<td>12</td>
</tr>
<tr>
<td>Dente Federico Lorenzo</td>
<td>19.c.1</td>
<td>17</td>
</tr>
<tr>
<td>Di Michiel James</td>
<td>19.c.5</td>
<td>17</td>
</tr>
<tr>
<td>Durand Patricia</td>
<td>19.b.5</td>
<td>16</td>
</tr>
<tr>
<td>Gao Yong-hua</td>
<td>19.a.8</td>
<td>15</td>
</tr>
<tr>
<td>Gian Yan Hui</td>
<td>18.a.6</td>
<td>12</td>
</tr>
<tr>
<td>Glodić Goran</td>
<td>18.a.7</td>
<td>12</td>
</tr>
<tr>
<td>Jakharia Kunal</td>
<td>18.c.9</td>
<td>14</td>
</tr>
<tr>
<td>Karamooz Elham</td>
<td>18.a.8</td>
<td>12</td>
</tr>
<tr>
<td>Keir Holly</td>
<td>19.c.3</td>
<td>17</td>
</tr>
<tr>
<td>Kim Soo Han</td>
<td>19.a.9</td>
<td>15</td>
</tr>
<tr>
<td>Laorden Daniel</td>
<td>19.b.6</td>
<td>16</td>
</tr>
<tr>
<td>Latisenko Rudolfs</td>
<td>19.b.2</td>
<td>16</td>
</tr>
<tr>
<td>LeClerc Isabelle</td>
<td>18.a.9</td>
<td>12</td>
</tr>
<tr>
<td>Lee Annemarie</td>
<td>19.c.8</td>
<td>17</td>
</tr>
<tr>
<td>Lotte Terpstra</td>
<td>18.a.10</td>
<td>12</td>
</tr>
<tr>
<td>Lv Qiadvting</td>
<td>19.b.7</td>
<td>16</td>
</tr>
<tr>
<td>Mäntylä Jarkko</td>
<td>18.a.11</td>
<td>12</td>
</tr>
<tr>
<td>Mariscal Aguilar Pablo</td>
<td>18.c.2</td>
<td>14</td>
</tr>
<tr>
<td>Maselli Diego</td>
<td>18.b.10</td>
<td>13</td>
</tr>
<tr>
<td>McLeese Rebecca H.</td>
<td>18.b.1</td>
<td>13</td>
</tr>
<tr>
<td>Méndez Raul</td>
<td>19.b.10</td>
<td>16</td>
</tr>
<tr>
<td>Mingora Christina</td>
<td>18.c.3</td>
<td>14</td>
</tr>
<tr>
<td>Morin Laurent</td>
<td>19.c.7</td>
<td>17</td>
</tr>
<tr>
<td>Nguyen Tu Quan</td>
<td>19.c.10</td>
<td>17</td>
</tr>
<tr>
<td>O’Donoghue Aisling</td>
<td>19.c.9</td>
<td>17</td>
</tr>
<tr>
<td>Obradovic Marko</td>
<td>18.c.4</td>
<td>14</td>
</tr>
<tr>
<td>Obradovic Marko</td>
<td>18.c.5</td>
<td>14</td>
</tr>
<tr>
<td>Obradovic Marko</td>
<td>18.c.6</td>
<td>14</td>
</tr>
<tr>
<td>O’Neill Katherine</td>
<td>18.b.2</td>
<td>13</td>
</tr>
<tr>
<td>O’Neill Katherine</td>
<td>18.b.3</td>
<td>13</td>
</tr>
<tr>
<td>Oriano Martina</td>
<td>18.b.4</td>
<td>13</td>
</tr>
<tr>
<td>Panciu Traian Constantin</td>
<td>18.b.9</td>
<td>13</td>
</tr>
<tr>
<td>Perea Lidia</td>
<td>19.b.3</td>
<td>16</td>
</tr>
<tr>
<td>Ray Animesh</td>
<td>19.a.10</td>
<td>15</td>
</tr>
<tr>
<td>Richardson Hollian</td>
<td>19.c.4</td>
<td>17</td>
</tr>
<tr>
<td>Sadigov Alizaman</td>
<td>19.c.2</td>
<td>17</td>
</tr>
<tr>
<td>Saliu Fabio</td>
<td>19.b.8</td>
<td>16</td>
</tr>
<tr>
<td>Shteinberg Michal</td>
<td>18.b.5</td>
<td>13</td>
</tr>
<tr>
<td>Smalley Katelyn</td>
<td>18.b.6</td>
<td>13</td>
</tr>
<tr>
<td>Spinou Arietta</td>
<td>18.b.7</td>
<td>13</td>
</tr>
<tr>
<td>Susa Ksenia</td>
<td>19.b.4</td>
<td>16</td>
</tr>
<tr>
<td>Taylor Steven</td>
<td>19.c.6</td>
<td>17</td>
</tr>
<tr>
<td>Torrente Anna</td>
<td>18.b.8</td>
<td>13</td>
</tr>
<tr>
<td>Wang Ping</td>
<td>18.c.8</td>
<td>14</td>
</tr>
</tbody>
</table>
16TH DECEMBER from 13.00 to 15.00 (CET)

**LIVE SESSION DAY 1**

Following participants’ request the “Meet the Professors” sessions will be only the following two.

Registrations for the below Courses will be open up to December 8th.

**PRE – REGISTRATION COMPULSORY**

Only 30 places available per course, confirmed on a first come first served basis.

---

**13.00 – 14.00**

**MEET THE PROFESSORS – ROUND 1**

Meet the Professors D

**Immunodeficiency: from diagnosis to management**

*Tanya Coulter, Belfast, UK* - *Alexandru Daniel Vlagea, Barcelona, Spain*

---

**14.00 – 15.00**

**MEET THE PROFESSORS – ROUND 2**

Meet the Professors A

**NTM – PD: the challenging diagnostic path**

*David E. Griffith, Denver, USA* - *Michael Loebinger, London, UK*
17TH DECEMBER from 12.30 to 16.00 (CET)

LIVE SESSION DAY 2

12.30 – 12.40 OPENING ADDRESS
Antoni Torres, Barcelona (Spain)
Francesco Blasi, Milan (Italy)
James D. Chalmers, Dundee (UK)

12.40 – 13.25 RISING STARS SESSION
Chairs: Antoni Torres, Barcelona (Spain), Francesco Blasi, Milan (Italy)

12.40 - 12.55 Rising Star Oral presentation (Bronchiectasis)
Sputum proteomics identifies mechanisms of disease severity and treatment response in bronchiectasis
Holly Keir, Dundee, UK
5’ questions time

13.00 - 13.15 Rising Star Oral presentation (NTM – PD)
Dual RNA-Seq of M. avium identifies characteristic host-pathogen interactions
Jodie Schildkraut, Nijmegen, The Netherlands
5’ questions time

13.20 - 13.25 Advice from Chairs to Rising Stars

13.25 – 13.55 KEYNOTE LECTURE
Chair: Oriol Sibila, Barcelona (Spain)

New bronchiectasis management in the COVID19 era
Tobias Welte, Hannover, Germany
SESSION I: NOVEL DIAGNOSTICS AND ASSESSMENT METHODS

Chairs: Felix Ringshausen, Hannover (Germany), 
       Michael Loebinger, London (UK)

13.55 – 14.15 Lung Function Testing Findings  
       Wei-Jie Guan, Guangzhou, China

14.15 – 14.35 Biomarkers to assess severity & prognosis  
       Stefano Aliberti, Milan, Italy

14.35 – 14.55 Quantitative chest computed tomography scoring technique for bronchiectasis (BEST-CT)  
       Jennifer Meerburg, Rotterdam, The Netherlands

14.55 – 15.15 Genetics and Bronchiectasis  
       Kenneth Olivier, Bethesda, USA

15.15 – 15.30 Discussion

15.30 – 16.00 VIRTUAL COCKTAIL
### LIVE SESSION DAY 3

**12.30 – 13.30**  
**SESSION II: INHALED TREATMENTS**

**Chairs:** James D. Chalmers, Dundee (UK),  
David de la Rosa Carrillo, Barcelona (Spain)

- **12.30 – 12.50**  
  *Should we need Inhaled Steroids?*  
  *Margot de Koning Gans, Christchurch, New Zealand*

- **12.50 – 13.10**  
  *Inhaled antibiotics: the iBest Example*  
  *Charles Haworth, Cambridge, United Kingdom*

- **13.10 – 13.20**  
  *Effect of treatment with the TOBI Podhaler® on the airway microbiota in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study*  
  *Gisli Einarsson, Belfast, United Kingdom*

- **13.20 – 13.30**  
  *Discussion*

---

**13.30 – 14.30**  
**SESSION III: FOCUS ON NON-TUBERCULOUS MYCOBACTERIA**

**Chair:** Miguel Angel Martinez-Garcia, Valencia (Spain), Kevin Winthrop, Portland (USA)

- **13.30 – 13.50**  
  *NTM transmission: state of the art*  
  *Andreas Floto, Cambridge, UK*

- **13.50 – 14.10**  
  *International guidelines on NTM*  
  *Jakko van Ingen, Nijmegen, The Netherlands*

- **14.10 – 14.20**  
  *Unravelling the role of type 1 interferons in lung chronic infections by M. Abscessus*  
  *Nicola Lorè, Milan, Italy*

- **14.20 – 14.30**  
  *Discussion*

---

**14.30 – 15.30**  
**LIVE SPONSORED SYMPOSIUM**  
*Please refer to page 21 for details*
## Poster Session 18.a, 15.45 – 17.00 (CET)

**Topics:** Bronchiectasis, Lung Function Testing  
**Chairs:** Michal Shteinberg (Israel)  
Antoni Torres (Spain)  
Tobias Welte, Hannover (Germany)

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Nationality</th>
<th>Abstract Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>18.a.1</strong> Athanazio Rodrigo Abensur</td>
<td>Brazil</td>
<td>Automated computed tomography lung densitometry in bronchiectasis patients</td>
</tr>
<tr>
<td><strong>18.a.2</strong> Athanazio Rodrigo Abensur</td>
<td>Brazil</td>
<td>Dynamic Hyperinflation and Exercise Intolerance in Bronchiectasis: Clinical, Radiological and Functional Correlation</td>
</tr>
<tr>
<td><strong>18.a.3</strong> Cabrera Roberto</td>
<td>Spain</td>
<td>High levels of resistance to recommended antimicrobial agents in Pseudomonas aeruginosa from patients with bronchiectasis</td>
</tr>
<tr>
<td><strong>18.a.4</strong> Crichton Megan L.</td>
<td>United Kingdom</td>
<td>Validation of the Bronchiectasis Impact Measure (BIM) – a novel patient reported outcome measure</td>
</tr>
<tr>
<td><strong>18.a.5</strong> De Vuono Maria Carmela</td>
<td>Italy</td>
<td>Voice of Patients in Bronchiectasis - a social media analysis</td>
</tr>
<tr>
<td><strong>18.a.6</strong> Giam Yan Hui</td>
<td>United Kingdom</td>
<td>Validation of AMP-activated protein kinase as a therapeutic target in bronchiectasis</td>
</tr>
<tr>
<td><strong>18.a.7</strong> Glodić Goran</td>
<td>Croatia</td>
<td>First Description of Bronchiectasis characteristics in Croatian patients – Data from the European Multicenter Bronchiectasis Audit and Research Collaboration</td>
</tr>
<tr>
<td><strong>18.a.8</strong> Karamooz Elham</td>
<td>United States of America</td>
<td>Pulmonary hypertension in bronchiectasis: A CT analysis from a cohort of the US Bronchiectasis and NTM Research Registry</td>
</tr>
<tr>
<td><strong>18.a.9</strong> LeClerc Isabelle</td>
<td>Canada</td>
<td>Innovative! Bronchiectasis! Education! Primary Care!</td>
</tr>
<tr>
<td><strong>18.a.10</strong> Lotte Terpstra</td>
<td>The Netherlands</td>
<td>Effects of long-term Tobramycin Inhalation Solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis The BATTLE Randomized Controlled Trial</td>
</tr>
<tr>
<td><strong>18.a.11</strong> Mäntylä Jarkko</td>
<td>Finland</td>
<td>Poor Physical Capacity in Bronchiectasis Patients Is Correlated with Poor Quality of Life</td>
</tr>
</tbody>
</table>
Poster Session 18.b, 15.45 – 17.00 (CET)

**Topic:** Bronchiectasis  
**Chairs:** Timothy Aksamit, Rochester (USA)  
James D. Chalmers (UK)

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Nationality</th>
<th>Abstract Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.b.5 Shteinberg Michal</td>
<td>Israel</td>
<td>Exploring factors associated with acquisition and chronicity of infection in bronchiectasis: a population based study</td>
</tr>
<tr>
<td>18.b.1 McLeese Rebecca H.</td>
<td>United Kingdom</td>
<td>Psychometric properties of health-related quality of life questionnaires for use in bronchiectasis clinical trials: A systematic review and meta-analysis</td>
</tr>
<tr>
<td>18.b.2 O’Neill Katherine</td>
<td>United Kingdom</td>
<td>Follow-up respiratory physiotherapy in bronchiectasis: A Northern Ireland survey</td>
</tr>
<tr>
<td>18.b.3 O’Neill Katherine</td>
<td>United Kingdom</td>
<td>Changes in Lung Clearance Index in the iBEST-1 study</td>
</tr>
<tr>
<td>18.b.4 Oriano Martina</td>
<td>Italy</td>
<td>Clinical characteristics associated with low sputum microbiome diversity in bronchiectasis</td>
</tr>
<tr>
<td>18.b.6 Smalley Katelyn</td>
<td>United Kingdom</td>
<td>Co-designing a digital self-management plan for bronchiectasis</td>
</tr>
<tr>
<td>18.b.7 Spinou Arietta</td>
<td>United Kingdom</td>
<td>Use of nebulized medications in people with bronchiectasis: a questionnaire for respiratory specialists</td>
</tr>
<tr>
<td>18.b.8 Torrente Anna</td>
<td>Spain</td>
<td>Screening non-tuberculous mycobacteria in patients with non-cystic fibrosis bronchiectasis</td>
</tr>
<tr>
<td>18.b.9 Panciu Traian Constantin</td>
<td>Romania</td>
<td>Insight into a Romanian group of bronchiectasis patients</td>
</tr>
<tr>
<td>18.b.10 Maselli Diego</td>
<td>United States of America</td>
<td>Small Airway Disease and Emphysema are Associated With Future Exacerbations in Smokers With Bronchiectasis</td>
</tr>
</tbody>
</table>
**Poster Session 18.c, 15.45 – 17.00 (CET)**

**Topics:**  
NTM – Non-Tuberculous Mycobacteria,  
PCD – Primary Ciliary Dyskinesia

**Chairs:**  
Stefano Aliberti (Italy)  
Francesco Blasi (Italy)  
Montserrat Vendrell (Spain)

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Nationality</th>
<th>Abstract Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkarni Meyad</td>
<td>United Kingdom</td>
<td>Neutrophil mediated control of Non Tuberculous Mycobacteria in patients with primary hypogammaglobulinaemia</td>
</tr>
<tr>
<td>Mariscal Aguilar Pablo</td>
<td>Spain</td>
<td>Comparison of spirometric changes in two different groups of patients with microbiological culture of Mycobacterium Abscessus.</td>
</tr>
<tr>
<td>Mingora Christina</td>
<td>United States of America</td>
<td>Time-to-detection as a pre-treatment predictor for culture conversion in patients with Non Tuberculous Mycobacteria Pulmonary Disease.</td>
</tr>
<tr>
<td>Obradovic Marko</td>
<td>Germany</td>
<td>Baseline characteristics and real-world treatment patterns of non-tuberculous mycobacterial lung disease (NTMLD) patients in community care setting in Germany</td>
</tr>
<tr>
<td>Obradovic Marko</td>
<td>Germany</td>
<td>Burden of non-tuberculous mycobacterial lung disease (NTMLD) in France: a claim database analysis</td>
</tr>
<tr>
<td>Obradovic Marko</td>
<td>Germany</td>
<td>Patient reported burden of Nontuberculous Mycobacterial Lung Disease (NTM-LD) – a patient survey in Germany</td>
</tr>
<tr>
<td>Wang Ping</td>
<td>United States of America</td>
<td>The Incremental Burden of Nontuberculous Mycobacterial Lung Disease (NTMLD) Among Patients with Bronchiectasis (BE): Hospitalizations and ER Visits Among US Medicare Beneficiaries</td>
</tr>
<tr>
<td>Jakharia Kunal</td>
<td>United States of America</td>
<td>Diagnostic Challenges in PCD: Need for Multiple Approaches</td>
</tr>
</tbody>
</table>
# Poster Session 19.a, 11.00 – 12.30 (CET)

**Topic:** Bronchiectasis  
**Chairs:** Stefano Aliberti (Italy), Wei-Jie Guan (China), Antoni Torres (Spain)

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Nationality</th>
<th>Abstract Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.a.1 Alfahl Zina</td>
<td>United Kingdom</td>
<td>Longitudinal assessment of sputum total bacterial, Pseudomonas aeruginosa and Haemophilus influenzae load in people with bronchiectasis when clinically stable and at the start and end of treatment of an exacerbation: Data from the BRONCH UK Study</td>
</tr>
<tr>
<td>19.a.2 Alhamed Alduihi Fatima</td>
<td>Syrian Arab Republic</td>
<td>CT findings in patients with Bronchiectasis</td>
</tr>
<tr>
<td>19.a.3 Bhatnagar Malvika</td>
<td>United Kingdom</td>
<td>Redesigning Bronchiectasis outpatient services post COVID-19 using patient satisfaction and preference data</td>
</tr>
<tr>
<td>19.a.4 Blamires Julie</td>
<td>New Zealand</td>
<td>Sore and Tired. The symptom experience of young people with bronchiectasis.</td>
</tr>
<tr>
<td>19.a.5 Bradley Judy M.</td>
<td>United Kingdom</td>
<td>Clinimetrics properties of objective outcome measures in the BronchUK study</td>
</tr>
<tr>
<td>19.a.6 Bradley Judy M.</td>
<td>United Kingdom</td>
<td>Clinimetrics properties of patient reported outcome measures to measure health-related quality of life in the BronchUK study</td>
</tr>
<tr>
<td>19.a.7 Bueno Freire Leticia</td>
<td>Spain</td>
<td>Longitudinal assessment of health-related quality of life in patients with bronchiectasis colonized by Pseudomonas aeruginosa</td>
</tr>
<tr>
<td>19.a.8 Gao Yong-hua</td>
<td>China</td>
<td>Detection and Quantification of microbiologic profiles of sputum at exacerbation in patients with bronchiectasis by using BioFire FilmArray Pneumonia Panel</td>
</tr>
<tr>
<td>19.a.9 Kim Soo Han</td>
<td>Korea (Republic of)</td>
<td>The characteristics and risk factors of bronchiectasis based on respiratory symptoms among the subjects who performed a medical check-up in a health-screening center</td>
</tr>
<tr>
<td>19.a.10 Ray Animesh</td>
<td>India</td>
<td>A study on the diagnostic accuracy of CT parameters for identification of recurrence of tuberculosis in post-tubercular bronchiectasis patients: Data from follow-up of 223 patients over 5 years</td>
</tr>
</tbody>
</table>
### Poster Session 19.b, 11.00 – 12.30 (CET)

**Topics:** Biomarkers, Cystic Fibrosis, Exacerbations  
**Chairs:** Francesco Blasi (Italy)  
Montserrat Vendrell (Spain)  
Tobias Welte (Germany)

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Nationality</th>
<th>Abstract Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abo-Leyah Hani</td>
<td>United Kingdom</td>
<td>Proteinase-3 as a biomarker of exacerbation in bronchiectasis</td>
</tr>
<tr>
<td>Latisenko Rudolfs</td>
<td>The Netherlands</td>
<td>Airway Path Tapering and Total Airway Count quantified on CT for Assessment of Bronchiectasis</td>
</tr>
<tr>
<td>Perea Lidia</td>
<td>Spain</td>
<td>Salivary SLPI and disease severity in Bronchiectasis</td>
</tr>
<tr>
<td>Suska Kseniia</td>
<td>Ukraine</td>
<td>Visceral fat as a predictor of the development of the T-helpers Type 2 airways inflammation in Bronchiectasis</td>
</tr>
<tr>
<td>Durand Patricia</td>
<td>Romania</td>
<td>Imaging features encountered in children with cystic fibrosis</td>
</tr>
<tr>
<td>Laorden Daniel</td>
<td>Spain</td>
<td>Comparative study of Mycobacterium abscessus infection between cystic fibrosis patients and non cystic fibrosis patients</td>
</tr>
<tr>
<td>Lv Qianting</td>
<td>The Netherlands</td>
<td>Computer aided diagnosis (CAD) for monitoring CF airway disease (CAD), the CAD-CAD method</td>
</tr>
<tr>
<td>Saliu Fabio</td>
<td>Italy</td>
<td>Nontypeable Haemophilus influenzae drives airway inflammation upon chronic infection</td>
</tr>
<tr>
<td>Alcaraz Victoria</td>
<td>Spain</td>
<td>Association between physical activity and risk of hospitalisation in bronchiectasis</td>
</tr>
<tr>
<td>Méndez Raúl</td>
<td>Spain</td>
<td>Acute and sustained IL-17a response in bronchiectasis exacerbations</td>
</tr>
</tbody>
</table>
## Poster Session 19.c, 11.00 – 12.30 (CET)

### Topics:
Asthma, Comorbidities, Microbiome & Mycobiome, PCD - Primary Ciliary Dyskinesia, Physiotherapy, Registries

### Chairs:
- James D. Chalmers (UK)
- Lucy Morgan (Australia)
- Michal Shteinberg (Israel)

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Nationality</th>
<th>Abstract Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.c.1 Dente Federico Lorenzo</td>
<td>Italy</td>
<td>Asthmatic traits in a group of patients with non cystic fibrosis Bronchiectasis</td>
</tr>
<tr>
<td>19.c.2 Sadigov Alizaman</td>
<td>Azerbaijan</td>
<td>Risk Factors for All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease: a 10-year follow-up study</td>
</tr>
<tr>
<td>19.c.3 Keir Holly</td>
<td>United Kingdom</td>
<td>Elevated sputum neutrophil elastase is predictive of microbiome dysbiosis and disease severity in bronchiectasis</td>
</tr>
<tr>
<td>19.c.4 Richardson Hollian</td>
<td>United Kingdom</td>
<td>Short-term stability of the lung microbiome in bronchiectasis and cystic fibrosis</td>
</tr>
<tr>
<td>19.c.5 Di Michiel James</td>
<td>Australia</td>
<td>Mucociliary clearance in the healthy trachea occurs in spirals and is impaired in COPD, and absent in primary ciliary dyskinesia and acute viral infection</td>
</tr>
<tr>
<td>19.c.6 Taylor Steven</td>
<td>Australia</td>
<td>Exploring the relationship between Pseudomonas aeruginosa, inflammation and bronchiectasis in a lung explant from a patient with primary ciliary dyskinesia</td>
</tr>
<tr>
<td>19.c.7 Morin Laurent</td>
<td>France</td>
<td>Feasibility and benefits of an innovative airway clearance device in COPD patients hospitalized for acute exacerbation</td>
</tr>
<tr>
<td>19.c.8 Lee Annemarie</td>
<td>Australia</td>
<td>“Teach me how to look after myself” - what people with bronchiectasis want from education in a pulmonary rehabilitation setting</td>
</tr>
<tr>
<td>19.c.9 O’ Donoghue Aisling</td>
<td>United Kingdom</td>
<td>The design and implementation of a Bronchiectasis Discharge Care Bundle</td>
</tr>
<tr>
<td>19.c.10 Nguyen Tu Quan</td>
<td>Australia</td>
<td>The Australian Bronchiectasis Registry: revision and improvement of a critical data collection platform to inform clinical care of bronchiectasis in Australia</td>
</tr>
</tbody>
</table>
19TH DECEMBER

LIVE SESSION DAY 4

12.30 – 13.20  SESSION IV: MICROBIOME NEW FRONTIERS

Chairs: Michal Shteinberg, Haifa, Israel
       Stefano Aliberti, Milan, Italy

12.30 – 12.45  Eradication in the era of microbiome
       James D. Chalmers, Dundee, UK

12.45 – 13.00  Functional effects of the microbiome / mycobiome
       Sanjay Chotirmall, Singapore, Singapore

13.00 – 13.15  Pseudomonas aeruginosa leading pathogen in the bronchiectasis microbiota?
       Antoni Torres, Barcelona, Spain

13.15 – 13.20  Discussion

13.20 – 13.50  SPONSORED CASE HISTORIES DISCUSSION

Please refer to page 21 for details

13.50 – 15.15  SESSION V: BRONCHIECTASIS ASSOCIATED DISEASES

Chairs: Gregory Tino, Philadelphia, USA
       Anne O’Donnell, Washington DC, USA

13.50 - 14.05  Bronchiectasis & NTM
       Felix Ringshausen, Hannover, Germany

14.05 - 14.20  Bronchiectasis in Severe Asthma: combined treatment options
       Francesco Blasi, Milan, Italy

14.20 - 14.35  Management of COPD and Bronchiectasis
       Ernesto Crisafulli, Verona, Italy

14.35 - 14.50  Alpha-1 antitrypsin deficiency
       Timm Greulich, Marburg, Germany

14.50 - 15.05  Aspergillus in Bronchiectasis
       Antony De Soyza, Newcastle, UK

15.05 – 15.20  Discussion

15.20-15.30  CLOSING ADDRESS & BEST POSTER AWARDS

Chairs: Antoni Torres, Barcelona (Spain), Francesco Blasi, Milan (Italy),
       James D. Chalmers, Dundee (UK)
SESSION A: CLINICAL TRIALS
Chair: Alan Barker, Portland (USA)

20 MINUTES Brensocatib in Bronchiectasis – WILLOW Study
James D. Chalmers, Dundee, UK

20 MINUTES Placebo effects in bronchiectasis
Yong-hua Gao, Zhengzhou, China

15 MINUTES Discussion

SESSION B: FOCUS on Bronchiectasis
Chair: Michael Loebinger, London (UK)

20 MINUTES Bronchiectasis insanity
Mark Metersky, Farmington, USA

20 MINUTES Implications of Pseudomonas aeruginosa biofilms in diagnosis, respiratory dysbiosis and exacerbations in non-Cystic Fibrosis Bronchiectasis
Laia Fernandez-Barat, Barcelona, Spain

10 MINUTES Discussion

SESSION C: THE PATIENTS’ POINT OF VIEW
Chair: Montserrat Vendrell, Girona (Spain)

15 MINUTES My experience with Bronchiectasis
Constança Pascual, Girona, Spain

15 MINUTES My experience with NTM
Aurora Massagué, Girona, Spain

10 MINUTES Discussion
30 MINUTES  |  Keynote lecture 1  
Bronchiectasis: need for better definitions  
*Rosario Menendez, Valencia, Spain*

30 MINUTES  |  Keynote lecture 2  
Research priorities in pulmonary NTM  
*Timothy Aksamit, Rochester, USA*

30 MINUTES  |  Keynote lecture 3  
Microbiome in Bronchiectasis and in NTM infections  
*Leopoldo Segal, New York, USA*

30 MINUTES  |  KEYNOTE lecture 4  
Lessons learnt from CF: implications for bronchiectasis  
*Stuart Elborn, Belfast, UK*

20 MINUTES  |  LECTURE 1  
Adultologists meet paediatricians: what are we supposed to know from our patient’s childhood that has an impact on the adulthood management  
*Adam Hill, Edinburgh, UK*

20 MINUTES  |  LECTURE 2  
Bronchiectasis exacerbation management  
*Anne Chang, Brisbane, Australia*

20 MINUTES  |  LECTURE 3  
Bronchiectasis: Dirty Little Secrets  
*Lucy Morgan, Sydney, Australia*

20 MINUTES  |  LECTURE 4  
Role of Registries: the Indian Example  
*Raja Dhar, Kolkata, India*
The following sessions are not part of the CME programme, both for UEMS/EAACME and EBAP procedures. Participants cannot claim credits for attending the following sessions.

LIVE SESSION DAY 3

18TH DECEMBER from 14.30 to 15.30 (CET)

LIVE SPONSORED SYMPOSIUM

Looking ahead - the changing landscape of MAC lung infection

Co-chairs Professor Stefano Aliberti and Professor Eva Polverino are joined in this roundtable session by an expert panel of Professor Michael Loebinger and Professor Nicolas Veziris to discuss their personal insights into the management of NTM.

Topics for discussion include:
- Advances and challenges in NTM management in 2020
- Impact of the 2020 NTM guidelines on clinical practice
- Role for new treatment options in MAC pulmonary disease

Supported by Insmed

LIVE SESSION DAY 4

19TH DECEMBER from 13.20 to 13.50 (CET)

LIVE CASE HISTORIES DISCUSSION

The bronchiectasis diagnostic conundrum: Results and implications from the pre-congress survey

Chair: Antoni Torres, Barcelona (Spain)
Speaker: Montserrat Vendrell, Barcelona (Spain)

Supported by Grifols
GENERAL INFORMATION

VIRTUAL EDITION

The 4th World Bronchiectasis & NTM Workshop is realised in virtual format. The virtual platform IS accessible only for registered participants from December 9th, 2020 to June 30th, 2021.
As per December 9th, 2020 registered participants may access the:
- Pre-recorded sessions
- Pre-recorded lectures and keynote lectures
- Published Poster Presentations in the Poster Lounge Area
Live sessions as per scientific programme will take place on December 16th – 19th. Check the programme for timing.
The lives sessions are recorded and made available to all registered participants from December 23rd, 2020 to June 30th, 2021.

PERSONAL CREDENTIALS

To access the 4th WBNC Virtual Platform use the credential you received when registering and reconfirmed with the confirmation letter received at beginning of December. Credentials are strictly personal and you should not share them with colleagues. Free name changes are always possible, please write to wbc@publiccreations.com. Name changes are guaranteed before December 15th and could not be so immediate during the dates of the live. Please note that each set of credential provides ONLY ONE ACCESS to the platform.

PERSONAL DATA

If you have accepted to be listed in the Participants List the following data will be visible to other participants.
- Picture (if provided)
- Surname / Name
- Role
- Department
- Institution / Company and address
- Telephone
- Email
- Website

NB: The mobile phone is used only by the secretariat and will not be published.

At any moment you can access from the platform the page “My Profile” and change the authorisation status. Please note that if you do not provide authorisation to share your data with the other registered participants you cannot access the data of other participants.
DIFFERENTIATED ACCESSES

Some contents are dedicated to Healthcare Professionals and cannot be accessed by other professionals.

Healthcare Professionals and Pharma Company staff members may access all the content of the platform with the exception of the Press Room.

Patient Associations Representatives may access all the content of the platform with the exception of promotional contents by Pharma Companies and Press Room.

Only Speakers can access the “Speakers Ready Room”.

Only Poster Presenters and Speakers can access the “Poster Presenters Ready Room”.

SPEAKERS READY ROOM

Only Speakers can access the Speakers Ready Room.

The speakers ready room is accessible every day from half an hour before the beginning to the end of the live programme. More precisely the Speakers ready room will be available in the following periods:

- December 16th – From 12:30 to 15:00 (CET Time)
- December 17th – From 12:00 to 16:00 (CET Time)
- December 18th – From 12:00 to 17:00 (CET Time)
- December 19th – From 10:30 to 15:30 (CET Time)

POSTER PRESENTERS READY ROOM & POSTERS SESSIONS

Poster Presenters and Speakers can access the Poster Presenter Ready Room starting from 30 minutes before each poster session. The Direction will split the poster presenters in the different poster sessions held in parallel.

Refer to the Scientific Programme to check which is the poster session your poster presentation is discussed in.

Each poster presentation should not exceed 5 minutes.

The best posters will receive the 4th WBNC Poster Award. Winners are disclosed in the Closing Address on December 19th at 15:20 (CET)

Poster Awards winners will benefit of recognition on the congress website and Abstracts Book and benefit of a free registration for the 2nd European NTM & Bronchiectasis Conference planned in Milan on July, 2nd – 3rd, 2021.

LIVE QUESTION CHATS AND LIVE POLL

The participation to live question chats and live polls during the live sessions is facultative.
NETWORKING OPPORTUNITIES

In the Networking Lounge you can see who is connected in each moment, chat with the other participants (general chat of the congress).

Furthermore, accessing the participants list you may download the virtual “Business Card” of other registered participants who have authorised, as yourself, to share their data. The Business Card includes e-mail and phone number to start, eventually, a personal conversation.

Also the side bar offers you the possibility to see who is on line in each moment. Please note that the person you call can refuse the call.

PRESENCE CONTROL

The virtual platform allows the Congress Secretariat to follow the path done by each participants within the platform.

These data are strictly confidential and are used only for:

• Issue a Certificate of Attendance only to attendees effectively present during the days of the live congress
• Issue CME Credits Certificate to attendees who have effectively followed the sessions.

The attendees who have authorised the publication of their data may share them with the relevant sponsor while entering their specific Partner Corporate Page

CERTIFICATE OF ATTENDANCE

The certificate of attendance is downloadable from the website at www.world-bronchiectasis-conference.org using the personal log-in credentials sent by e-mail, starting from December 22nd 2020.

For Sponsored Groups: Please note that in order to provide the certificate of attendance to each participant, we need the personal e-mail address.

The Certificate of attendance will only be delivered to those having attended the Conference.

CME ACCREDITATION

4th World Bronchiectasis & NTM Conference, 16/12/2020-19/12/2020 has been granted 16 European CME credits by the European Board for Accreditation in Pneumology (EBAP) and 8 CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®)

The Credits Certificate is only be delivered to those having attended the Conference.

To download your certificate please log in the website www.world-bronchiectasis-conference.org using the personal log-in credentials sent by e-mail, starting from December 22nd, 2020. CME Credits certificates are downloadable up to January 11th. After this date, in order to comply with the reporting deadline of UEMS, the CME Credits are no longer downloadable.

For Sponsored Groups: Please note that in order to provide the CME certificate to each participant, we will need their personal e-mail address.

LANGUAGE

The official language of the Conference is English. No simultaneous translation will be provided.
2nd European NTM & Bronchiectasis Workshop

Milan, Università Statale
01 - 03 July 2021

ORGANISING COMMITTEE
STEFANO ALIBERTI (Italy)
FRANCESCO BLASI (Italy)
JAMES D. CHALMERS (UK)

SCIENTIFIC COMMITTEE
STUART ELBORN (UK)
PIETER C. GOEMINNE (Belgium)
CHARLES S. HAWORTH (UK)
MICHAEL LOEBINGER (UK)
ANTONI TORRES (Spain)
TOBIAS WELTE (Germany)

TOPICS
- Bronchiectasis
- Cystic Fibrosis
- Epidemiology
- Etiology
- Exacerbations
- Imaging
- Immunology
- International Guidelines
- Modifiable risk factor
- NTM
- Paediatrics
- Treatments
- Surgery

CALL FOR ABSTRACT
March 29th, 2021

www.ntmbronchiectasis.org
mail: ntmbronchiectasis@publiccreations.com
The Committee is grateful to

Platinium Sponsor

insmed®

Gold Sponsors

Boehringer Ingelheim
Zambon
GRIFOLS

Supporter

CSL Behring

Biotherapies for Life™

Media Partner

www.world-bronchiectasis-conference.org